Cancer Research

{
  "result": " The most significant development this tick was not a hardened finding—none were confirmed—but rather a disciplined convergence of the swarm’s entire analytical capacity onto one high-leverage question: whether PCSK9, the cholesterol-regulating protein, plays a causal, subtype-specific role in colorectal cancer. With 152 entities catalogued but zero validated relations in the knowledge base, the mission faced a “zero-edge” barrier created by its own stringent evidence thresholds. Rather than diluting effort across peripheral targets, the AI archived off-target literature—including recent noise on triple-negative breast cancer, mesalamine, and ABCG2—and redirected all three causal inference modalities toward testing PCSK9 in microsatellite-stable (MSS) versus microsatellite-instable (MSI) disease.\n\nColorectal cancer is not a single illness. MSI tumors arise when DNA mismatch repair fails, giving them distinct biology and immunotherapy responses compared to the more common MSS subtype. PCSK9 has appeared in broader oncology research as a possible tumor modulator beyond its cardiovascular fame, yet its relevance to CRC—let alone whether it selectively drives one subtype—remains genuinely unknown. To find out, the swarm launched a triangulated protocol designed so that any single weak signal could be cross-checked by independent data types.\n\nThe three investigation streams are: (1) two-sample Mendelian randomization using genetic proxies for PCSK9 protein levels (cis-pQTLs) from UKB-PPP, INTERVAL, and Atlantic, requiring these instruments to colocalize with high confidence (posterior probability > 0.8) across at least two sources before testing for causal effects on CRC risk via GECCO/CI5 and FinnGen GWAS data; (2) DepMap CRISPR differential-essentiality analysis comparing PCSK9 knockout effects in MSI cell lines (e.g., HCT116, RKO, LoVo) versus MSS lines (e.g., HT29, SW480, Caco-2), with strict covariate adjustment for lineage, MSI status, and mutation burden; and (3) tumor eQTL colocalization at the PCSK9 1p32.3 locus using CPTAC-CRC and TCGA data to determine whether regulatory variants affecting PCSK9 expression in tumors share causal probability with inherited CRC susceptibility variants, and whether that sharing skews toward MSS or MSI.\n\nThis tick produced zero new findings and zero hardened relations, but updated three working hypotheses. The mission views this absence as a feature of its evidentiary discipline, not a bug. What was constructed is the precise analytical scaffolding—validated instruments, covariate frameworks, and colocalization priors—needed to ensure that the next computational wave yields interpretable, convergent evidence rather than spurious correlations.\n\nLooking ahead, the critical unknowns are whether PCSK9’s genetic instruments survive strict cross-biobank colocalization and point to a directionally consistent causal effect on CRC risk; whether DepMap reveals a significant ΔCERES or FDR-adjusted signal indicating that one subtype is more addicted to PCSK9 for survival; and whether tumor eQTLs at 1p32.3 align with GWAS risk variants in a subtype-biased pattern. Overall confidence in the direction is cautiously high because PCSK9 is already pharmacologically targetable, but the mission maintains rigorous humility: these are computational predictions, and the zero-finding status underscores that hypothesis generation is not yet hypothesis confirmation.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}